Ambroxol
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Ambroxol
- Molecular weight
- 378.11
- Structure (SMILES)
- Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1
- 4 hydroxydemethylbromhexine trans
- 4-HYDROXYDEMETHYLBROMHEXINE, TRANS-
- ambroxol
- Ambroxol
- ambroxol [INN]
- AMBROXOL [MI]
- Ambroxol [WHO-DD]
- Ambroxol Hydrochloride
- Ambroxol Hydrochloride (420mg)
- Ambroxol hydrochloride (Mucoangin?)
- Ambroxol hydrochloride 30 mg
- Ambroxol injection
- ambroxol inn
- ambroxol mi
- Ambroxol Spray
- ambroxol who dd
- tabcin
- Tabcin
- CAS registry numbers
- 18683-91-5
- ChEMBL ID
- CHEMBL153479
- InChIKey
- JBDGDEWWOUBZPM-XYPYZODXSA-N
- FDA ingredient codes (UNII)
- 200168S0CL
- R02AD05
- R05CB06
Sources for recorded values
- 625
- 438399
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- ambroxol
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- glucosylceramidase beta
- Gene symbol
- GBA1
- Protein identifier
- P04062
- Condition
- Respiratory Tract Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000684
- Subject identifier
- D012140
- Condition
- Lewy Body Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006792
- Subject identifier
- D020961
- Condition
- Dementia
- Highest recorded phase
- 2
- Condition identifier
- HP:0000726
- Subject identifier
- D003704
- Condition
- Cough
- Highest recorded phase
- 2
- Condition identifier
- HP:0012735
- Subject identifier
- D003371
- Condition
- Pharyngitis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002258
- Subject identifier
- D010612
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Parkinson Disease
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Gaucher Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018150
- Subject identifier
- D005776
- Condition identifier
- EFO_0000684
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006792
- Condition identifier
- EFO_0009661
- Condition identifier
- HP_0001097
- Highest recorded phase
- 1
- Condition identifier
- HP_0012735
- Highest recorded phase
- 2
- Condition identifier
- HP_0100543
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001627
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002258
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003781
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005087
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005244
- Condition identifier
- MONDO_0006733
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007488
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009267
- Condition identifier
- MONDO_0018150
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018150
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018937
- Highest recorded phase
- 2
- Condition identifier
- Orphanet_77259
- Highest recorded phase
- 2
- Condition identifier
- Orphanet_77261
- Event
- acute kidney injury
- Reports
- 11
- Reporting signal score
- 8.81166
- Event
- allergic sinusitis
- Reports
- 2
- Reporting signal score
- 9.05323
- Event
- amniotic fluid index increased
- Reports
- 2
- Reporting signal score
- 16.7136
- Event
- anal erosion
- Reports
- 2
- Reporting signal score
- 11.9195
- Event
- anaphylactoid reaction
- Reports
- 3
- Reporting signal score
- 7.54634
- Event
- application site erythema
- Reports
- 5
- Reporting signal score
- 13.2182
- Event
- application site pain
- Reports
- 5
- Reporting signal score
- 12.5375
- Event
- atrial fibrillation
- Reports
- 13
- Reporting signal score
- 18.2564
- Event
- atrioventricular block complete
- Reports
- 9
- Reporting signal score
- 28.5647
- Event
- benign prostatic hyperplasia
- Reports
- 5
- Reporting signal score
- 16.8482
- Event
- blister
- Reports
- 6
- Reporting signal score
- 8.38067
- Event
- blood creatine phosphokinase increased
- Reports
- 10
- Reporting signal score
- 17.5605
- Event
- blood creatinine increased
- Reports
- 7
- Reporting signal score
- 7.29717
- Event
- brain natriuretic peptide increased
- Reports
- 4
- Reporting signal score
- 13.5504
- Event
- chest discomfort
- Reports
- 9
- Reporting signal score
- 10.1762
- Event
- chorea
- Reports
- 3
- Reporting signal score
- 10.889
- Event
- conjunctivitis
- Reports
- 6
- Reporting signal score
- 13.387
- Event
- cyanosis
- Reports
- 4
- Reporting signal score
- 7.42025
- Event
- discordant twin
- Reports
- 2
- Reporting signal score
- 16.7136
- Event
- dysphonia
- Reports
- 6
- Reporting signal score
- 8.42884
- Event
- dyspnoea exertional
- Reports
- 5
- Reporting signal score
- 7.05917
- Event
- eczema
- Reports
- 4
- Reporting signal score
- 6.27011
- Event
- erythema
- Reports
- 11
- Reporting signal score
- 9.67998
- Event
- eyelid function disorder
- Reports
- 2
- Reporting signal score
- 9.03181
- Event
- foetal macrosomia
- Reports
- 2
- Reporting signal score
- 10.0185
And 43 more, listed on the interactive page.
- NCT00144274
- NCT00148499
- NCT00525044
- NCT03583658
- NCT01463215
- NCT03950050
- NCT02914366
- NCT02941822
- NCT05287503
- NCT05778617
- NCT05830396
- NCT06193421
- NCT03415269
- NCT03843541
- NCT04405596
- NCT04588285
- NCT05959850
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 3
- Polar surface area
- 58.28
- Calculated partition coefficient (ALogP)
- 3.19
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 18
- Molecular formula
- C13H18Br2N2O
- Natural product
- Yes
These details could not be displayed.
Related records
Trials (35)
- A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
- A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS
- A Drug-Drug Interaction Study of Ambroxol and Levodropropizine
- A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
- A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
- A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
- A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.
- Ambroxol as a Disease-modifying Treatment in GBA-PD
- Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia
- Ambroxol as a Treatment for Parkinson's Disease Dementia
- Ambroxol in Disease Modification in Parkinson Disease
- Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
- Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis
- Ambroxol Spray Sore Throat Study
- Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy
- Ambroxol to Slow Progression in Parkinson Disease
- An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
- Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
- Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
- Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat
In development for (7)
- Amyotrophic lateral sclerosis Phase 2
- Dementia Phase 2
- Gaucher disease Phase 2
- Lewy body dementia Phase 1
- Parkinson disease Phase 3
- Pharyngitis Phase 3
- Respiratory system disorder Phase 3
Other linked conditions (2)
- Bronchitis
- Gaucher disease type III